Arena Pharmaceuticals Inc.

64.56-1.34-2.03%Vol 141.71K1Y Perf 30.41%
Apr 19th, 2021 13:27 DELAYED
BID64.45 ASK64.58
Open65.02 Previous Close65.90
Pre-Market- After-Market-
 - -%  - -
Target Price
91.38 
Analyst Rating
Strong Buy 1.00
Potential %
41.39 
Finscreener Ranking
★★★★     55.07
Insiders Trans % 3/6/12 mo.
-100/-76/-89 
Value Ranking
★★★★+     59.80
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★+     56.38
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap3.90B 
Earnings Rating
Sell
Price Range Ratio 52W %
43.55 
Earnings Date
6th May 2021

Today's Price Range

64.2867.00

52W Range

44.7990.19

5 Year PE Ratio Range

-56.5011.70

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-0.59%
1 Month
-14.75%
3 Months
-18.14%
6 Months
-18.56%
1 Year
30.41%
3 Years
77.96%
5 Years
256.22%
10 Years
410.85%

TickerPriceChg.Chg.%
ARNA64.56-1.3400-2.03
AAPL134.380.22000.16
GOOG2 299.641.88000.08
MSFT258.40-2.3400-0.90
XOM56.21-0.4500-0.79
WFC44.040.20000.46
JNJ162.410.17000.10
FB301.87-4.3100-1.41
GE13.35-0.0400-0.30
JPM153.22-0.0800-0.05
Financial StrengthValueIndustryS&P 500US Markets
19.00
19.60
0.04
0.04
-88.50
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
-125 458.00
-124 249.00
-25 610.60
47.34
RevenueValueIndustryS&P 500US Markets
57.00K
0.00
-55.19
-40.50
Earnings HistoryEstimateReportedSurprise %
Q04 2020-1.97-2.10-6.60
Q03 2020-1.92-1.6911.98
Q02 2020-2.08-1.6122.60
Q01 2020-2.26-2.0011.50
Q04 2019-1.62-1.76-8.64
Q03 2019-1.36-1.46-7.35
Q02 2019-1.02-1.24-21.57
Q01 201911.4312.105.86
Earnings Per EndEstimateRevision %Trend
3/2021 QR-2.19-8.96Negative
6/2021 QR-2.26-17.10Negative
12/2021 FY-8.11-9.59Negative
12/2022 FY-5.81-18.33Negative
Next Report Date6th May 2021
Estimated EPS Next Report-2.19
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume141.71K
Shares Outstanding60.34M
Trades Count2.92K
Dollar Volume29.39M
Avg. Volume496.20K
Avg. Weekly Volume337.39K
Avg. Monthly Volume423.29K
Avg. Quarterly Volume497.71K

Arena Pharmaceuticals Inc. (NASDAQ: ARNA) stock closed at 65.9 per share at the end of the most recent trading day (a -3.07% change compared to the prior day closing price) with a volume of 684.16K shares and market capitalization of 3.90B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 363 people. Arena Pharmaceuticals Inc. CEO is Amit D. Munshi.

The one-year performance of Arena Pharmaceuticals Inc. stock is 30.41%, while year-to-date (YTD) performance is -14.23%. ARNA stock has a five-year performance of 256.22%. Its 52-week range is between 44.79 and 90.19, which gives ARNA stock a 52-week price range ratio of 43.55%

Arena Pharmaceuticals Inc. currently has a PE ratio of -9.00, a price-to-book (PB) ratio of 3.71, a price-to-sale (PS) ratio of 68 548.60, a price to cashflow ratio of 4.50, a PEG ratio of 2.32, a ROA of -32.78%, a ROC of -30.74% and a ROE of -36.02%. The company’s profit margin is 47.34%, its EBITDA margin is -124 249.00%, and its revenue ttm is $57.00 Thousand , which makes it $0.00 revenue per share.

Of the last four earnings reports from Arena Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-2.19 for the next earnings report. Arena Pharmaceuticals Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for Arena Pharmaceuticals Inc. is Strong Buy (1), with a target price of $91.38, which is +41.39% compared to the current price. The earnings rating for Arena Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Arena Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Arena Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 12.15, ATR14 : 3.59, CCI20 : -64.14, Chaikin Money Flow : -0.18, MACD : -3.26, Money Flow Index : 34.79, ROC : -1.96, RSI : 45.52, STOCH (14,3) : 21.42, STOCH RSI : 0.69, UO : 32.28, Williams %R : -78.58), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Arena Pharmaceuticals Inc. in the last 12-months were: Amit D. Munshi (Option Excercise at a value of $5 835 755), Amit D. Munshi (Sold 406 194 shares of value $28 047 382 ), Christopher Cabell (Option Excercise at a value of $341 640), Christopher Cabell (Sold 13 000 shares of value $884 000 ), Jayson Dallas (Buy at a value of $678), Jayson Dallas (Sold 1 327 shares of value $106 824 ), Manmeet Singh Soni (Sold 3 262 shares of value $197 704 ), Nova Susan Tina (Option Excercise at a value of $627 200), Nova Susan Tina (Sold 34 600 shares of value $2 350 606 ), Robert Lisicki (Option Excercise at a value of $1 945 125), Robert Lisicki (Sold 51 372 shares of value $3 536 439 ), Vincent Aurentz (Option Excercise at a value of $386 354), Vincent Aurentz (Sold 27 524 shares of value $1 839 562 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
5 (100.00 %)
3 (75.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
1 (25.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.50

Arena Pharmaceuticals Inc.

Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

CEO: Amit D. Munshi

Telephone: +1 858 453-7200

Address: 6154 Nancy Ridge Drive, San Diego 92121, CA, US

Number of employees: 363

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

67%33%

Bearish Bullish

58%42%

Bearish Bullish

61%39%

News

Stocktwits